Status:
COMPLETED
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
American Rhinologic Society
Conditions:
Epistaxis
Hereditary Hemorrhagic Telangiectasia
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemor...
Detailed Description
Ninety percent of patients who suffer from Hereditary Hemorrhagic Telangiectasia (HHT) experience epistaxis which can range from mild to recurrent, severe, life threatening episodes. Current methods t...
Eligibility Criteria
Inclusion
- a clinical diagnosis of HHT based on the Curacoa Criteria
- age 18 and older
- cognitive ability and willingness to sign the study consent form and complete the study forms and questionnaires
Exclusion
- previous sclerotherapy with Sodium Tetradecyl Sulfate
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01408732
Start Date
February 1 2011
End Date
September 1 2014
Last Update
November 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota Otolaryngology Clinic
Minneapolis, Minnesota, United States, 55455